Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
NCT05176665 · View on ClinicalTrials.gov ↗
Study Summary
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
Conditions Studied
Interventions
- DRUG EMB-01
Study Locations (14)
Other
- Hunan Cancer Hospital — Changsha
- West China Hospital, Sichuan University — Chengdu
- The Sixth Affiliated Hospital of Sun Yat-Sen University — Guangzhou
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou
- Harbin Medical University Cancer Hospital — Harbin
- Shandong Cancer Hospital — Jinan
- Gansu Provincial Hospital — Lanzhou
- The Affiliated hospital of Qingdao University — Qingdao
- Fudan University Shanghai Cancer Center — Shanghai
- The First Affiliated Hospital of Xi'an Jiaotong University — Xi'an
- First Affiliated Hospital of Zhengzhou University — Zhengzhou
Texas
- MD Anderson Cancer Center — Houston
Beijing Municipality
- Beijing cancer Hospital — Beijing
Guangdong
- Nanfang Hospital — Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05176665
The ClinicalTrials.gov registry entry for NCT05176665 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanghai EpimAb Biotherapeutics Co., which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention — of which EMB-01 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05176665 reports 14 study locations spanning 4 distinct geographic areas — top geographies include Other, Texas, Beijing Municipality. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05176665 about?
NCT05176665 is a clinical study titled "EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers". This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
What is the current status of trial NCT05176665?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2021-10-21. Estimated completion is 2025-12-31.
What conditions does trial NCT05176665 study?
This clinical trial studies the following conditions: Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05176665?
The interventions under investigation include: EMB-01 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05176665?
This trial is sponsored by Shanghai EpimAb Biotherapeutics Co., which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05176665 being conducted?
This trial has 14 study locations across Texas, Beijing Municipality, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.